Essentials of Oncology, Solid Organ and Blood/Marrow Transplant Management for the Health Care Team Day 2
TUESDAY, APRIL 17, 2018 — Attending the full daily program will earn 5.75 contact hours (.575 CEUs). ACPE UAN 0860-0000-18-003-L01-P/0860-0000-18-003-L01-T
Treatment Strategies for Acute Lymphoblastic Leukemia: From Adolescents to Adults, Michael Verneris, MD, Children's Hospital Colorado
Acute lymphoblastic leukemia (ALL) is a disease that affects infants, children, adolescents and adult patients. Adolescents and young adults (AYAs) with ALL pose unique challenges and issues beyond those faced by adults. This session will discuss therapies used to treat ALL in both AYAs and adults and highlight treatment strategies for both newly diagnosed and relapsed/refractory ALL in AYA and adult populations.
Improving Safety of Allotransplantation: Current and Emerging Strategies for the Prevention of Graft-versus-Host Disease, Nandita Khera, MD, MPH, Mayo Clinic
Graft-versus-host disease (GvHD) represents the most serious and challenging complication of allogeneic hematopoietic stem-cell transplantation (HSCT). This session will discuss its pathophysiology, assessment of patient risk for GvHD, diagnostic challenges, management recommendations, prevention and emerging therapeutic treatment options.
New Insights into Chimeric Antigen Receptor (CAR) T-Cell Therapy, Kara Davis, DO, The Lucile Salter Packard Children's Hospital
Early outcomes from CAR T-cell trials have generated impressive results in patients with blood cancers. Clinical trials of CAR T-cell therapy have involved pediatric and adult patients with blood-based cancers, such as leukemia and lymphoma. Pipeline therapeutics are in early stages of development. This session will discuss the latest advances in CAR T-cell therapies and promising pipeline therapeutics.
Infectious Disease in Blood/Marrow Transplantation, Sanjeet S. Dadwal, MD, FACP, City of Hope
Certain factors place individuals undergoing a blood/marrow transplant (BMT) at increased risk for infections. Despite recent advances in supportive care, growth factors, more-potent antimicrobials, prophylaxis strategies, and new diagnostic techniques, infections remain the major causes of mortality in individuals who undergo a BMT.
The Impact of Timely Referrals for Blood/Marrow Transplantation on Patient Outcomes and Transplant Success, Linda J. Burns, MD, National Marrow Donor Program/Be The Match
Studies on blood/marrow transplantation (BMT) have revealed that transplant success can be highly dependent upon transplant timing. Early referral is a critical factor for optimal transplant outcomes. This session will discuss referral timing guidelines and highlight disease categories that include patients at risk for disease progression. The impact of timely referrals on the outcomes and success of BMT will also be discussed.
Therapeutic Strategies in the Treatment of Hodgkin Lymphoma, Matthew Lunning, DO, University of Nebraska Medical Center
Treatment of Hodgkin lymphoma is tailored to disease type, disease stage and an assessment of the risk of resistant disease. The current treatment of Hodgkin lymphoma seeks to maximize the risk-benefit ratio of treatment. This session will discuss therapeutic strategies in the treatment of Hodgkin lymphoma with a focus on tailoring therapy to each patient according to age and his/her risk of short- and long-term toxicity and/or relapse.
- 5.75 ACPE - Pharmacists
- 5.75 ACPE - Pharmacy Technicians